Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants Nicole Germino - Truist Securities Gena Wang - Barclays Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Lisa Walter - RBC Operator Good afternoon, and we ...

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.25%. A quarter ago, it was expected that this drug developer would post a loss of $0.22 per share when it actually produced a loss of $0.27, delivering a surprise of -22.73%. Over the last four quarters, the compa ...

Table of Contents Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2024 FINANCIAL RESULTS • Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone payments, plus tiered royalties on net sales. • Reported Pfizer's announcement of positive topline r ...

Sangamo Therapeutics (NASDAQ:SGMO) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat "certain neurodegenerative diseases." That includes the company's proprietary zinc finger repressors for Alzheimer's disease. This agreement will see Sangamo handle technology transfer and some preclinical activities. G ...

SGMO 12 month stock chart on 07/22/24 (Seeking Alpha) Discussion on Financials Isa-vec is a GTx designed to carry the DNA for human alpha-Gal A to the liver of Fabry patients by a single IV infusion so that the liver can start producing functional alpha-Gal-A. The ph1/2 STAAR clinical trial (NCT04046224) dosed 24 patients who were either on ERT, been off it for 6 months or more, or were ERT-naïve. Dr. Robert Hopkin of Cincinnati Children's Hospital Medical Center was one of the investigators in the trial an ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants James Stamos - Jefferies Gena Wang - Barclays Luis Santos - H.C. Wainwright Ritu Baral - TD Cowen Bill Chappell - Truist Operator Good day, and welcome to the ...

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.73%. A quarter ago, it was expected that this drug developer would post a loss of $0.25 per share when it actually produced a loss of $0.34, delivering a surprise of -36%.Over the last four quarters, the compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 501 Canal Blvd., Richmond, California, 94804 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS RICHMOND, California, May 9, 2024 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results. "Sangamo continues to progress its neurology-focused genomic medicine pipeline as most recently showcased at the 27 ASGCT Annual Meeting, with foundational advances across our epigenetic regulation programs and capsid ...